Glenn Pierce compensation by year
Voyager Therapeutics Summary Compensation Table · the one fiscal year held| Component | FY2021 |
|---|---|
| Salary | $293,272 |
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $259,407 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $0 |
| Total | $552,679 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Voyager Therapeutics, Inc. DEF 14A filed April 21, 2022, accession 0001558370-22-005685, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Voyager Therapeutics, Inc. filed document, accession 0001558370-22-005685. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 25,004 | — | $4.23 |
| Option | 21,000 | — | $4.45 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Voyager Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2021 proxy (filed April 21, 2022)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-09 | Grant or award derivative | — | 30,000 | $0.00 | 30,000 |
| 2025-06-03 | Grant or award derivative | — | 24,000 | $0.00 | 24,000 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Voyager Therapeutics’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| G. Andre Turenne | Former President and Chief Executive Officer | $2,630,096 |
| Robert Hesslein | Senior Vice President and General Counsel | $1,314,955 |
| Allison Dorval | Former Chief Financial Officer | $1,131,523 |
| Omar Khwaja | Former Chief Medical Officer and Head of Research and Development | $996,529 |
| Michael Higgins | Former Interim President and Chief Executive Officer | $696,063 |
| Glenn Pierce · this page | Interim Chief Scientific Officer | $552,679 |
Board service
Voyager Therapeutics board · FY2021–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $51,000 | $0 | $53,760 | $0 | $104,760 |
| FY2024 | $51,000 | — | $144,000 | $0 | $195,000 |
| FY2023 | $51,000 | — | $197,780 | $0 | $248,780 |
| FY2021 | $21,888 | — | $259,407 | $0 | $281,295 |
Each year as the company reported it in Voyager Therapeutics's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Voyager Therapeutics pays directors a $40,000 cash retainer. As stated in Voyager Therapeutics's FY2025 proxy.
Committees
Compensation · Science and Technology
The full Voyager Therapeutics compensation record
free company briefThis page is one person within Voyager Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Voyager Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Voyager Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.